Medicare gets AI-powered push to take meds, save money on generics
H.R. 1142 — To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes. · Filed by David Schweikert (R-AZ) · Introduced Feb 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Secretary of Health and Human Services to create guidelines aimed at getting Medicare patients to take their prescribed drugs 90% of the time. The guidelines must use artificial intelligence and machine learning, and should encourage the use of cheaper generic and biosimilar drugs where possible.
Why we flagged it
The bill is a straightforward directive to establish clinical guidelines aimed at improving medication adherence and reducing drug costs for Medicare beneficiaries. It is a public-health intervention, not a regulatory carve-out or appropriation.
What the text implies
- AI/ML-driven adherence monitoring may create detailed patient behavioral data; privacy safeguards are not addressed in the bill itself and would depend on HHS implementation.
- Promotion of generics and biosimilars may reduce revenue for brand-name manufacturers, creating potential industry resistance to aggressive guideline implementation.
- Guidelines are advisory (the bill does not mandate patient compliance or provider enforcement), so real-world adherence gains depend on voluntary adoption and incentive design.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Medication adherence reduces hospitalizations, complications, and mortality; promoting generics and biosimilars lowers patient costs. The bill imposes no restrictions on citizens' rights or remedies—it directs the government to improve a public health outcome.
Who stands to gain
- generic drug manufacturers
- biosimilar manufacturers
- Medicare (reduced costs from lower drug prices and fewer complications)
Named in the bill
HHS Secretary, Medicare Part B, Medicare Part D, Social Security Act, Public Health Service Act
Where it stands
- Feb 7, 2025 — Introduced · Congress.gov: “Introduced in House”
- Feb 7, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (962 characters) on Jun 8, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Medicare gets AI-powered push to take meds, save money on generics” QuorumCivic. https://share.quorumcivic.app/bill/119/hr1142 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.